http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1680136-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a95df0b144acafc4f622dad6c213d0a7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2004-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da60407f4af5d16827f68c9b2d4a77a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0c293d6723f0b6f4292e9676e7da2ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d50306556921fc45ae0c19ea8f3142a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03066c0e575fb1872666be189497f827 |
| publicationDate | 2006-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1680136-A1 |
| titleOfInvention | Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics |
| abstract | The invention relates to cyclised peptides corresponding to sequence SEQ ID N DEG 1: X1X2RGDX3FGX4X5LLFIHFX6IGSX7HSX8IX9, wherein: the letters without any numerical index correspond to amino acids defined by the single-letter international code; X1 is G or GG having an amino-terminal end which may or may not be free; X2 is either a C, in which case X2 = X4, the two Cs being connected by a disulphide bridge, or X2 is capable of forming a lactam bridge with X4, either X2 or X4 being an amino acid bearing an acid group, such as A or D, and the other bearing an amino function such as Q, N; X3 is either an M pattern or a norleucine pattern; X5 is one or several di-, tri-, or tetra-peptide patterns comprising G or a combination of G and S, or X5 is a C pattern having a side-chain which serves as a covalent linkage point with a 3-nitro-2-pyridinesulphenyl group which is located at the N-terminal end of the next amino acid (L); X6 is either an R pattern or a K pattern; X7 is either an R pattern or a K pattern; X8 is either an R pattern or a K pattern; and X9 is an aliphatic amino acid (such as G or A) having an amide C-terminal end. The inventive peptides can be used as active ingredients in medicaments, for example, for the treatment of pathologies linked to hypervascularisation. |
| priorityDate | 2003-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.